Califf Supports Changing Combo Product Pathway; FDA Developing Proposal
This article was originally published in The Tan Sheet
Executive Summary
FDA concepts for a new pathway could be ready for congressional scrutiny within a year, commissioner nominee Robert Califf says during his confirmation hearing.
You may also be interested in...
Senate Bill Aims At Streamlining Combination Product Regulation
A Senate bill would streamline device/drug combination registrations by letting FDA rely on prior PMAs and approved drug findings to help support new product approvals, among other reforms. It was introduced by Sen. Johnny Isakson, R-Ga., and co-sponsored by Sens. Robert Casey, D-Pa., and Pat Roberts, R-Kansas.
Combo Product Reforms Are A Priority For Next User Fee Round, FDA Officials Say
Top FDA officials, including CDRH Director Jeffrey Shuren and FDA Deputy Commissioner Robert Califf, are sending strong signals that the designation and review processes for combination products are due for a significant reassessment. That should be a priority topic of upcoming user fee negotiations with industry, they say.
Podcast: FDA's Califf Talks About Combo Product Reform, Commish Prospects
In an exclusive interview with "The Gray Sheet," FDA's Deputy Commissioner Robert Califf spoke about concerns the agency has with regulating combination products, provides tips for companies looking to get combo products to market and whether he'd consider taking on the role of FDA commissioner. Listen to our exclusive podcast or read the Q&A transcript.